ASTX029 (ERK inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- April 28, — Biomed Valley Discoveries Phase 1/2 Trial: Ulixertinib + Ruxolitinib for Myelofibrosis: cross-connection with ulixertinib-ruxolitinib-combination: Both target the ERK/MAPK pathway in MPN; ulixertinib+ruxolitinib is the first clinical combination test of ERK1/2 inhibition with a JAK backbone, while ASTX029 represents a parallel ERK inhibitor program — together establishing ERK/MAPK as a tractable downstream-of-JAK target class. (novelty: 4)
- 2026-02-13 — Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms: Phase I/II dose-finding trial (trial-early) of ASTX029 + ASTX727 in RAS pathway-mutant MDS and MDS/MPN — first-in-class ERK inhibitor + oral HMA combination exploiting ERK/MAPK dependency in a genomically defined subpopulation. (novelty: 4) (novelty: 4)
Open questions
Related
Contributing findings
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
13-feb-2026
novelty 4
per-area 5
introduces